Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Cancers|January 28, 2026
Oncological Outcomes and Genomic Features of Gastric-Type Endocervical Adenocarcinoma, the Most Aggressive and Common HPV-Independent Cervical CancerMing Du, Zhen Zheng, Peiyao Lu, et al.
BMC Cancer|August 18, 2022
CDC50A might be a novel biomarker of epithelial ovarian cancer-initiating cellsJie Yin, Yiping Wen, Jing Zeng, et al.
Cancers|October 14, 2022
Using Patient-Derived Xenograft (PDX) Models as a 'Black Box' to Identify More Applicable Patients for ADP-Ribose Polymerase Inhibitor (PARPi) Treatment in Ovarian Cancer: Searching for Novel Molecular and Clinical Biomarkers and Performing a Prospective Preclinical TrialJiayu Chen, Yan Li, Haiyuan Wang, et al.
Obstetrics and Gynecology|November 22, 2012
Management of intravenous leiomyomatosis with intracaval and intracardiac extensionJinhui Wang, Jiaxin Yang, Huifang Huang, et al.
Frontiers in Oncology|October 21, 2021
Patient-Derived Xenografts Are a Reliable Preclinical Model for the Personalized Treatment of Epithelial Ovarian CancerJiayu Chen, Ying Jin, Siyi Li, et al.
Molecular Cancer Therapeutics|July 5, 2021
Real-world Experience of Olaparib Treatment in Patients with Ovarian Cancer: A Chinese Multicenter StudyHong Zheng, Yunong Gao, Hongyan Guo, et al.
Annals of Translational Medicine|March 17, 2020
Chinese expert consensus on the prevention of abdominal pelvic adhesions after gynecological tumor surgeriesJinghe Lang, Ding Ma, Yang Xiang, et al.
JAMA Oncology|July 13, 2023
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical TrialNing Li, Jianqing Zhu, Rutie Yin, et al.
CA: a Cancer Journal for Clinicians|November 25, 2025
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trialLingying Wu, Jing Wang, Qingshui Li, et al.
Pageof 6